Aptose Biosciences Provides Update on Reverse Stock Split
05 juin 2023 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 05, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
31 mai 2023 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Enters into $25 Million Committed Equity Facility
25 mai 2023 16h14 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
23 mai 2023 17h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Reports Results for the First Quarter 2023
08 mai 2023 16h01 HE
|
Aptose Biosciences, Inc.
─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet...
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
04 mai 2023 07h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted...
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
24 avr. 2023 07h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral...
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
28 mars 2023 16h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
09 mars 2023 16h05 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
02 mars 2023 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...